Jada Bascom Foundation
All conditions

Inherited metabolic disorders

Adult-onset metachromatic leukodystrophy

Also called: Adult MLD · AO-MLD · ARSA deficiency · metachromatic leukodystrophy · MLD · Adult arylsulfatase A deficiency · Adult metachromatic leukodystrophy

What a donor has to do with this

A transplant is not a standard part of treating this condition. It is used rarely, in particular situations, and most people diagnosed with it will not have one.

This is our reading of published transplant guidelines for this condition, not a measurement of how many people need a donor. Where a source actually counted donors, the figure and the people it counted are shown further down. Where none did, we say so rather than estimate.

This page is not written out in full yet

We have not written this condition out in full yet. What is on this page — how a donor fits in, who it affects, and the sources behind that — is researched and linked, but the plain-English explanation of the condition itself is still to come.

What the evidence says

Who it affects
Typical onset/diagnosis: adult MLD begins after age 16, sometimes in the fourth or fifth decade, in both sexes and represents about 10–20% of MLD. Evidence: U.S. GeneReviews (revised 2024) and a German four-patient series diagnosed at ages 17–37; no markedly enriched population was identified.
Treatments other than a transplant
Supportive neurologic, psychiatric, rehabilitative, and palliative care — standard noncurative management — multiple regions — No approved gene-therapy indication for adult-onset MLD.
If a transplant is used, the cells come from
bone marrow: used in 2 of 4 adults in the 2024 German single-center case series; mobilized peripheral blood stem cells: used in 2 of 4 adults in the 2024 German single-center case series; umbilical cord blood: not reported in the 2024 German adult case series; dominance: bone marrow and peripheral blood were tied at 2 grafts each in the 2024 German four-adult series
How often the donor was unrelated
Not reported. No source we could read states this for this condition, so we do not give a number. An estimate here would be a guess dressed as evidence.

Where this gets complicated

Evidence is limited to the 2024 German single-center series of four adults with approximately one year of neurologic follow-up; this supports a rare, selected role.; In the 2024 German four-adult series, three achieved full donor chimerism and remained neurologically stable at one year; the fourth deteriorated.

Registries need people

An unrelated donor is not a usual part of treating this condition. Registering still matters, for the many conditions where it is.

Joining a registry is a cheek swab and a short health form. You are not matched to a condition — you are matched to a person, and it could be someone with any of the conditions in this library. You are contacted only if you turn out to be a possible match for someone, and you can ask questions and decline before anything else happens.

Find your registry

Related conditions

Others in inherited metabolic disorders. They are genuinely different diseases with different treatments — the group name is not a diagnosis.

Where this came from